The long-term prognostic value of multiple biomarkers following a myocardial infarction

Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

“…To the best of our knowledge, this is one of the first studies to evaluate a multimarker approach for the prediction of baseline risk of long-term death in patients undergoing PPCI for STEMI. In another study of 298 patients receiving revascularization or thrombolysis for MI, a multimarker approach with NT-proBNP, CRP, matrix metalloproteinase-9, pregnancy-associated plasma protein A, myeloperoxidase, soluble CD40 ligand, and fibrin monomer rendered no additional prognostic information beyond conventional risk stratification tools (12). A key factor in explaining these different results may be the timing of biomarker assessment.…”

Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases

“…In ACS patients baseline BNP levels correlated with the risk of death, HF, AMI and subsequent ventricular remodeling in the short and long term. This association remained significant in subgroups of patients who had AMI with ST-segment elevation (STEMI), patients who had AMI without ST-segment elevation (NSTEMI) and in patients who had unstable angina [23][24][25][26]. BNP is at least as good as the GRACE score in predicting outcomes following AMI and, when added to the GRACE score and to established risk factors, it also improves the prediction accuracy [27,28].…”

Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease

“…Among the abundant supply of biomarkers, which have been discussed in the past as valuable agents for risk stratification in patients with ACS [8][9][10], copeptin has recently been shown to improve the early diagnosis of ACS in the emergency department [11,12]. Indeed, whilst the plasma concentration levels of copeptin drop rapidly after the onset of chest pain, the concentration of troponin conversely rises [12], and copeptin may thus provide a means to bridge the "troponin-blind" intervals in the early hours after acute myocardial infarction (AMI).…”